- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07635576
Effect of Gastric Electrical Stimulation on Serum Insulin Levels
Defining the Effect of Gastric Electrical Stimulation on Serum Insulin Levels in Human Subjects
The goal of this study is to determine how much effect turning off an individual's Gastric Electrical Stimulator (GES) for up to four hours will have on levels of insulin, C-peptide, GLP-1 and glucose levels.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Up to thirty-two adult patients with gastroparesis who have undergone implantation of a gastric stimulation device at least three months prior may participate in this study, which will be completed at a single study visit.
The study consists of two groups, an EXPERIMENTAL group that undergoes turning off the GES and a CONTROL group that does not undergo the turning off of the GES. The subjects are randomized to either the control or experimental group.
After an overnight fast, consented and eligible patients are placed in the supine position on a hospital bed, and an intravenous line is inserted and capped. EKG electrodes will be placed on the chest, arms/legs, behind each ear and just under the jaw on each side to record cardiac and vagal nerve activity.
The study consists of three separate and consecutive periods:
- Baseline, a 20-minute period during which GES is left ON at each patient's pre-study settings;
- Experimental, a 4-hour period during which the GES device is turned OFF for participants in the experimental group;
- Recovery, a 20-minute period during which GES is turned back ON to the patient's pre-study settings for participants in the experimental group.
A 5-ml sample of blood will be collected from each patient after placement of the flexible IV catheter secured with tape, and after the Baseline, and Recovery study periods. During the Experimental period a blood sample is withdrawn after 30 minutes and then again at the 1-hour, 2-hour, 3-hour and 4-hour intervals through a flexible IV catheter secured with tape, with the possibility of up to 8 blood draws over the duration of the study. EKG and vagal nerve activity will be recorded continuously through the 3 study periods.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Thomas V Nowak, MD
- Numero di telefono: 3179484272
- Email: tvnowak@iu.edu
Backup dei contatti dello studio
- Nome: Maureen V Schilling, BS
- Numero di telefono: 3172782064
- Email: maschi@iu.edu
Luoghi di studio
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Indiana University Hospital
-
Investigatore principale:
- Thomas V Nowak, MD
-
Contatto:
- Maureen V Schilling, BS
- Numero di telefono: 3172782064
- Email: maschi@iu.edu
-
Contatto:
- Thomas V Nowak, MD
- Numero di telefono: 317-948-4272
- Email: tvnowak@iu.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- At least 18 years of age.
- Documented diagnosis of gastroparesis
- Not taking diabetic prescribed exogenous insulin.
- Patient has a GES device that has been implanted for at least 3 months.
- Willing to give up to 8 blood samples.
- Willing to lie in a bed for up to 5.5 hours.
Exclusion Criteria:
- Pregnancy
- History of allergic reaction to EKG lead placement adhesives.
- Unable to give informed consent.
- Unwilling to give up to 8 5 ml blood samples.
- Unwilling to lie in a bed for up to 5.5 hours.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: The OFF Group
This group of subjects will have their GES interrogated and observed as well as having the device turned off for the duration of the experiment. The device will then be re-interrogated and turned back on at the end of the experiment. |
Device will either be turned off for the duration of the experimental period.
Altri nomi:
|
|
Nessun intervento: Control Group
This group of subjects will undergo the same procedures as the experimental group, except that their GES will not be turned off during the experimental period. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in serum insulin
Lasso di tempo: Day 1
|
To define the effect of prolonged four-hour withdrawal of gastric electrical stimulation on serum insulin. |
Day 1
|
|
Change in serum C-peptide
Lasso di tempo: Day 1
|
To define the effect of prolonged four-hour withdrawal of gastric in human subjects. Insulin and C-peptide are co-primary end points. |
Day 1
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Changes in serum glucose
Lasso di tempo: Day 1
|
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation. |
Day 1
|
|
Changes in serum GLP-1
Lasso di tempo: Day 1
|
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation. |
Day 1
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Thomas V Nowak, MD, IU School of Medicine/IU Health
Pubblicazioni e link utili
Pubblicazioni generali
- van der Voort IR, Becker JC, Dietl KH, Konturek JW, Domschke W, Pohle T. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):38-42. doi: 10.1055/s-2004-830525.
- Vosseler A, Zhao D, Fritsche L, Lehmann R, Kantartzis K, Small DM, Peter A, Haring HU, Birkenfeld AL, Fritsche A, Wagner R, Preissl H, Kullmann S, Heni M. No modulation of postprandial metabolism by transcutaneous auricular vagus nerve stimulation: a cross-over study in 15 healthy men. Sci Rep. 2020 Nov 24;10(1):20466. doi: 10.1038/s41598-020-77430-2.
- Kozorosky EM, Lee CH, Lee JG, Nunez Martinez V, Padayachee LE, Stauss HM. Transcutaneous auricular vagus nerve stimulation augments postprandial inhibition of ghrelin. Physiol Rep. 2022 Apr;10(8):e15253. doi: 10.14814/phy2.15253.
- Payne SC, Ward G, Fallon JB, Hyakumura T, Prins JB, Andrikopoulos S, MacIsaac RJ, Villalobos J. Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol Rep. 2022 Apr;10(8):e15257. doi: 10.14814/phy2.15257.
- Hampton RF, Jimenez-Gonzalez M, Stanley SA. Unravelling innervation of pancreatic islets. Diabetologia. 2022 Jul;65(7):1069-1084. doi: 10.1007/s00125-022-05691-9. Epub 2022 Mar 29.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 30020
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .